Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor

By Dani Kass · May 28, 2024, 4:22 PM EDT

Edwards Lifesciences has petitioned the full Federal Circuit to narrow its interpretation of a U.S. Food and Drug Administration safe harbor that essentially allows patent infringement during drug development, arguing that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Petition

Case Information

Case Title

Edwards Lifesciences Corporation v. Meril Life Sciences Pvt. Ltd.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

June 07, 2022

Recent Articles By Dani

November 06, 2024
How The Patent System May Look After Trump's Return
October 17, 2024
Justices Urged To Fix 'Novel Misreading' Of IP Safe Harbor
October 07, 2024
Fed. Circ. Questions If Safer OxyContin Profits Came From IP
September 27, 2024
Kappos' Bayh-Dole Warning To Clients Draws Debate
September 24, 2024
Novo Nordisk Tells Sens. Ozempic Costs Are Linked To PBMs
August 13, 2024
Entresto Release Delayed As Novartis Goes To Fed. Circ.
August 06, 2024
Fed. Circ. Told Edwards Filed Safe Harbor Suit With Bad Intent
July 10, 2024
Drug Pricing, Overreach Dominate IP Disclaimer Feedback
April 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor
February 20, 2024
Fed. Circ. Backs Microsoft's PTAB Win Over 3D Patents